OVERALL This application seeks continued support for the Washington University DDRCC (WU-DDRCC). The overall objective of the WU-DDRCC is to create an infrastructure that supports collaborative, multidisciplinary investigation into host-environment interactions in digestive disease. The WU-DDRCC provides enabling technology that promotes the basic and translational research interests of its 50 Full + 22 Associate members, and nurtures career development of junior investigators. Our Research Base is highly productive as evidenced by 248 original peer reviewed publications citing the DDRCC (60% reflecting collaborations involving two or more members), including 58 in journals with impact factors >10, and increased funding support ($23.8M?$30.9M; 30% increase since 2013). Our members have appointments in 13 different Departments across Washington University. The Research Base interests are organized around three mechanistic themes: (1) Host-microbial interactions, inflammation and mucosal immunity; (2) Stem cells, epithelial renewal, paligenosis and cancer; (3) Metabolic homeostasis, nutrient transport and enterohepatic signaling. The Research Base is supported by three Biomedical Cores that leverage institutional resources, and which have evolved in response to members' needs to provide a cost-effective infrastructure. These Cores include (1) Advanced Imaging and Tissue Analysis Core (AITAC), which provides sophisticated imaging technologies; (2) A new Precision Animal Models and Organoids Core (PAMOC), which provides mouse genetic services and organoid technologies; and (3) a Biobank Core, which provides access to clinical biospecimens from normal and disease states. These Cores are overseen by a responsive Administrative Core (ARAC), guided by both Internal and External Advisory Boards to promote collaborative and synergistic interactions and support Biomedical Cores and services that reflect current and future needs of the Research Base with state-of-the-art services and specialized expertise, delivered cost- effectively and efficiently. The WU-DDRCC also supports a scientific Enrichment Program sponsoring visiting researchers and workshops to augment the scientific milieu, promote collaboration and stimulate development of new initiatives in digestive disease. The Enrichment Program also promotes academic career development by nurturing the interests of postdoctoral trainees, fellows and junior faculty, including promoting diversity in the workforce through a targeted Underrepresented Minority speaker program. The WU-DDRCC has invested significant resources and effort in building a pipeline of future leaders in digestive disease research by supporting and nurturing new investigators through an annual Pilot and Feasibility Program for which there is greater than 39:1 return on investment over the last 15 Years (3 cycles) of this award. In addition, the WU-DDRCC is committed to promoting and sharing technology development with NIDDK funded Centers locally as well as other DDRCCs regionally, through the Midwest Alliance and the NIDDK Center program. Collectively, these accomplishments serve to advance discovery in digestive disease that will impact patient care.

Public Health Relevance

OVERALL Research supported through the WU DDRCC has and will continue to have a profound impact on understanding the pathophysiology of digestive disease and the role of host-environment interactions. The WU DDRCC also promotes scientific collaboration and synergies that ultimately will identify new therapeutic opportunities with the potential for rapid translation into clinical trials for patients with digestive diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK052574-22
Application #
10129349
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Perrin, Peter J
Project Start
2000-03-01
Project End
2024-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
22
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Strubberg, Ashlee M; Veronese Paniagua, Daniel A; Zhao, Tingting et al. (2018) The Zinc Finger Transcription Factor PLAGL2 Enhances Stem Cell Fate and Activates Expression of ASCL2 in Intestinal Epithelial Cells. Stem Cell Reports 11:410-424
Patel, A; Hasak, S; Nix, B D et al. (2018) Genetic risk factors for perception of symptoms in GERD: an observational cohort study. Aliment Pharmacol Ther 47:289-297
Hibberd, Timothy J; Feng, Jing; Luo, Jialie et al. (2018) Optogenetic Induction of Colonic Motility in Mice. Gastroenterology 155:514-528.e6
Mayer, Allyson L; Zhang, Yiming; Feng, Emily H et al. (2018) Enhanced Hepatic PPAR? Activity Links GLUT8 Deficiency to Augmented Peripheral Fasting Responses in Male Mice. Endocrinology 159:2110-2126
Wardill, Hannah R; Van Sebille, Ysabella Z A; Ciorba, Matthew A et al. (2018) Prophylactic probiotics for cancer therapy-induced diarrhoea: a meta-analysis. Curr Opin Support Palliat Care 12:187-197
Osaki, Luciana H; Bockerstett, Kevin A; Wong, Chun Fung et al. (2018) Interferon-? directly induces gastric epithelial cell death and is required for progression to metaplasia. J Pathol :
Chandrasekaran, Sukantha; Burnham, Carey-Ann D; Warner, Barbara B et al. (2018) Carriage of Cronobacter sakazakii in the Very Preterm Infant Gut. Clin Infect Dis 67:269-274
Tarr, Gillian A M; Oltean, Hanna N; Phipps, Amanda I et al. (2018) Case definitions of hemolytic uremic syndrome following Escherichia coli O157:H7 infection vary in validity. Int J Med Microbiol 308:1121-1127
Wang, Songyan; Oestricker, Lauren Z; Wallendorf, Michael J et al. (2018) Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance. PLoS One 13:e0192441
Jiang, Hongmei; Xu, Mai; Li, Lin et al. (2018) Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. Mol Cancer Ther 17:2144-2155

Showing the most recent 10 out of 899 publications